HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) web only table Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Thien, F. Search for Related Content PubMed PubMed Citation Articles by Thien, F.

Once daily oral controller therapy with low dose theophylline or montelukast was not effective in poorly controlled asthma

Clinical impact ratings GP/FP/Primary care IM/Ambulatory care Respirology Allergy & immunology

Key Words: acetates • anti asthmatic agents • asthma • leukotriene antagonists • quinolines • theophylline

The first 150 words of the full text of this article appear below.

METHODS
Design: randomised placebo controlled trial.

Allocation: {concealed^*}.

Blinding: blinded (clinicians, patients, {data collectors, outcome assessors, and data safety and monitoring committee}).^*

Follow up period: 24 weeks.

Setting: 19 American Lung Association Asthma Clinical Research Centres (ALA-ACRC) in the US.

Patients: 489 patients 15 years of age (mean age 40 y, 74% women, 61% white) who were diagnosed with asthma, were prescribed daily asthma medication for 1 year, had FEV₁ 50% of the predicted value, and had poor asthma control (score 1.5 on the Asthma Control Questionnaire [ACQ]). Patients continued their baseline medications. Exclusion criteria were use of oral corticosteroids, leukotriene antagonists, or theophylline within 4 weeks before randomisation; 20 pack years history of smoking; or significant illness.

Intervention: theophylline, 300 mg/day (n = 161); montelukast, 10 mg/day (n = 164); or placebo (n = 164).

Outcomes: annualised rate of episodes of poor asthma control (EPAC) (composite end . . . [Full text of this article]

Francis Thien, MD, FRACP

Box Hill Hospital and Monash University,
Victoria, Melbourne, Australia